Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh

Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh

KKRX:950160
10,900.00
KRW
-340.00
(-3.02%)
-3,486.64EPS
9.04TMarket Cap
Mar 23Next Earn
Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh
KRX:950160
(Korea Stock Exchange)

Recent

price

10,900.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
764.48
79.3
62.22
49.67
58.24
65.38
142.65
51.68
65.93
62.78
64.67
Revenue per Share
-150.8
-1,128.6
-530.4
-818.2
-684.4
-773.6
-168
-240.2
-439.2
-2,343.8
-3,486.64
Basic EPS, GAAP
-215.58
-972.54
-645.27
-748.93
-638.16
-753.8
-771.18
-980.45
-1,269.62
-1,721.82
-1,423.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
718.9
13,243.09
2,249.96
1,507.96
787.12
596.9
1,328.02
1,581.2
1,833.82
756.22
1,473.24
Book Value per Share
689.87
13,149.56
2,152.78
1,502
782.58
504.34
874.76
375.45
-683.26
-2,925.27
-2,725.2
Tangible Book Value per Share
17
40
61
61
61
61
66
72
77
82
82
Basic Weighted Avg Shares
13,295
3,192
3,785
3,035
3,556
4,003
9,456
3,706
5,073
5,159
5,331
Sales/Revenue/Turnover
-29.54
-1,276.33
-870.13
-1,488.63
-1,168.68
-1,171.65
-172.41
-553.26
-433.58
-432.73
-421.91
Operating Margin (%)
381
564
676
1,289
1,642
1,551
1,665
1,412
809
784
851
Depreciation Expense
-2,622
-45,433
-32,265
-49,989
-41,788
-47,370
-11,136
-17,224
-33,799
-192,587
-287,403
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-19.73
-1,423.23
-852.4
-1,647.16
-1,175.21
-1,183.31
-117.77
-464.76
-666.19
-3,733.25
-5,391.61
Profit Margin (%)
21,066
176,423
143,545
96,078
47,817
27,306
51,466
17,727
-63,695
-269,390
-254,449
Working Capital
16,919
18,750
13,976
16,456
9,367
6,578
6,273
5,568
5,274
4,145
4,119
LT Debt
8,778
160,107
137,288
92,164
48,108
38,648
91,489
114,963
145,904
64,081
124,838
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-53.83
-21.7
-43.57
-59.58
-109.21
-17.12
-16.69
-25.91
-183.43
-186.31
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
71,889
75,416
60,874
LT Borrowings
- -
- -
- -
LT Finance Leases
4,351
4,145
4,119
Preferred Equity and Hybrid Capital
2
2
2
Shares Outstanding
83
85
85
Market Capitalization
3,982,138
6,744,990
9,041,337

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
129,084
86,292
127,016
Cash, Cash Equivalents & STI
117,976
82,091
122,092
Accounts Receivable, Net
365
180
152
Inventories
39
60
25
Total Current Liabilities
218,173
355,682
381,465
Payables & Accruals
- -
- -
- -
ST Debt
71,889
75,416
60,874
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
22.71%
-56.08%
Free Cash Flow
- -
30.1%
44.8%
Net Income, GAAP
- -
111.52%
469.81%
Sales/Revenue/Turnover
- -
25.31%
1.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,213
959
2,098
779
5,073
2025
1,288
1,344
1,716
861
5,159
2026
1,410
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-53.2
-70.2
-78.4
-236.24
-439.2
2025
-72.6
-702.6
-76.2
-1,489.11
-2,343.8
2026
-1,198.6
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kolon TissueGene, Inc. (KOSDAQ: 950160) develops cell and gene therapies for orthopedic diseases and degenerative disorders including osteoarthritis of the knee, hip, and spine; rheumatoid arthritis; meniscus injuries; spinal disc disease; and nerve regeneration. The company offers core pipeline products comprising TG-C (Invossa), a genetically engineered allogeneic cell therapy in Phase 3 trials in the U.S. for knee osteoarthritis involving over 1,000 patients with topline results expected mid-2026; TG-B for bone regeneration; TG-D for disc regeneration; and TG-N for nerve regeneration; alongside applications in musculoskeletal disorders and veterinary medicine for knee osteoarthritis. Founded in 1999 and headquartered in Rockville, Maryland, USA, Kolon TissueGene conducts operations primarily in the United States with a focus on major markets such as the U.S., Europe, and Japan, supported by affiliates including Kolon Life Science and Kolon Biotech for integrated R&D, production, and clinical development. In recent developments, the company completed Phase 3 patient dosing for TG-C in July 2024, presented long-term safety data and potential U.S. FDA pathways at the OARSI World Congress in April 2025, participated in BIO International Convention and BIO US 2025 to pursue commercialization strategies including partnerships with Big Pharma and specialty firms, and advanced construction of TG-C-specific production facilities as of early 2025 while exploring market expansion amid positive analyst outlooks for Phase 3 success in July 2026. Kolon TissueGene, formerly TissueGene, Inc., changed its name in March 2018 and employs approximately 29 people under President and CEO Moon Jong Noh.